Skip to main content

Table 1 Baseline characteristics of patients in the longitudinal pediatric- and adult-onset systemic lupus erythematosus (pSLE and aSLE) cohorts*

From: Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus

  pSLE Pediatric controls aSLE Adult controls
Sex, ratio, male:female, 10:32 10:12 2:21 16:24
Ethnicity/race, n (%)     
   Hispanic 21 (50) 5 (23) 2 (9) 6 (15)
   Asian 10 (24) 10 (45) 2 (9) 13 (32)
   Caucasian 5 (12) 6 (27) 13 (56) 16 (40)
   African-American 4 (9) 1 (5) 4 (17) 4 (10)
   Other/Mixed 2 (5) 0 2 (9) 1 (3)
Age, years 15.9 ± 3.5 20.2 ± 1.3 42 ± 15 41 ± 10
Age at diagnosis, years 12.7 ± 4.1   32 ± 15  
Disease duration, years 3.1 ± 3   7.9 ± 8.6  
SLEDAI, mean (range) 2.0 (0, 15)   3.0 (0, 12)  
SDI, mean (range) 0.9 (0, 5)   0.9 (0, 2)  
Glomerulonephritis, n (%)†† 30 (71)   5 (22)  
   Class II 0   0  
   Class III 0   0  
   Class IV 17 (40)   4 (17)  
   Class V 6 (14)   0  
   Mixed 5 (12)   0  
  1. *Except where indicated otherwise, values are expressed as the mean ± SD and were obtained at the time of study entry. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; Glomerulonephritis classification as per the International Society of Nephrology/Renal Pathology Society. There was no biopsy done on one aSLE patient with clinical criteria of SLE renal disease. P = 0.002 in pSLE compared with aSLE; ††P = 0.0005 in pSLE compared with aSLE.